Innate Pharma S.A.
IPHA
$1.36
-$0.06-4.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.29% | -16.39% | -36.03% | -127.42% | -552.82% |
| Total Depreciation and Amortization | -27.54% | -34.59% | -39.44% | -54.21% | -60.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 313.26% | 502.00% | 1,259.88% | 164.29% | -29.35% |
| Change in Net Operating Assets | -126.84% | -123.75% | -113.49% | 298.07% | 222.05% |
| Cash from Operations | -693.31% | -284.24% | -129.31% | 6.96% | 78.79% |
| Capital Expenditure | 62.40% | 56.46% | 48.66% | 18.38% | -11.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.46% | -27.55% | -29.57% | -42.08% | -53.96% |
| Cash from Investing | -19.73% | -27.23% | -29.77% | -42.87% | -55.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.28% | -26.62% | -72.97% | -137.25% | -278.48% |
| Issuance of Common Stock | 411.65% | 967.41% | 12,590.71% | 3,768.22% | 641.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 197.22% | 233.34% | 276.61% | 135.83% | -205.67% |
| Foreign Exchange rate Adjustments | 319.51% | 397.74% | 714.40% | 65.70% | -284.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -860.50% | -900.10% | -1,052.66% | -33.21% | 69.04% |